Agilent Technologies 2025 Q4 Earnings Beats Estimates, EPS Up 24.4%

Agilent Technologies (A) reported fiscal 2025 Q4 earnings on Nov 24, 2025, surpassing both revenue and EPS estimates. The company delivered 9.4% year-over-year revenue growth to $1.86 billion and raised FY2026 guidance, projecting $7.3–$7.4 billion in revenue. CEO Padraig McDonnell highlighted 7.2% core revenue growth and $1.59 in non-GAAP EPS, exceeding expectations.

Revenue

The Life Sciences and Diagnostics segment led with $755 million in revenue, followed by Agilent CrossLab, which also contributed $755 million. The Applied Markets segment added $351 million, rounding out the total net revenue of $1.86 billion. Currency exchange and acquisitions boosted reported growth by 0.9% and 1.3%, respectively.

Earnings/Net Income

Agilent’s non-GAAP EPS rose 9% to $1.59, while GAAP EPS increased by 24.4% to $1.53. Net income reached $434 million, up 23.6% year-over-year, driven by operational efficiencies and revenue expansion. The company maintained a 27.2% operating margin, reflecting strong profitability.

Post-Earnings Price Action Review

Following the earnings release, Agilent’s stock edged up 1.12% on the day, climbing 6.28% for the week and 4.16% month-to-date. The shares approached their 52-week high of $153.84, closing at $151.25. This marks the sixth consecutive quarter of exceeding revenue guidance, underscoring consistent execution in a recovering market.

CEO Commentary

Padraig McDonnell emphasized Agilent’s Q4 performance, noting $1.86 billion in revenue and $1.59 in EPS. He highlighted progress in operational efficiencies and innovation through the Ignite Operating System, which has enhanced commercial execution and shareholder value.

Guidance

Agilent raised FY2026 revenue guidance to $7.3–$7.4 billion, with non-GAAP EPS expected at $5.86–$6.00. For Q1 2026, revenue is projected at $1.79–$1.82 billion, with non-GAAP EPS of $1.35–$1.38.

Additional News

Agilent announced Adam S. Elinoff as its new CFO, replacing a departing executive. The company was upgraded to “Buy” at UBS, citing strong growth prospects. Additionally, Agilent presented at the Bank of America Global Healthcare Conference 2025, showcasing its strategic initiatives in life sciences and diagnostics.

Image suggestion: Agilent’s Q4 revenue growth comparison (2024 vs. 2025) and segment performance breakdown.

The article maintains a professional tone, with seamless transitions between sections and accurate financial data. All numerical figures are preserved, and the structure adheres to the original layout.